PMC 7843845
Klinic advises patients considering Ozempic off-label for weight loss to explore medications explicitly approved for this purpose
For many patients, the clinical benefits of GLP-1sparticularly sustained weight loss and metabolic improvementsare closely tied to continued use.[166] Once treatment is discontinued, individuals often experience weight regain and the return of obesity-related health conditions, underscoring the need to view obesity as a chronic condition that may require long-term treatment.[167] Adherence is also influenced by treatment tolerability.[168] While GLP-1s are generally well tolerated, side effects such as gastrointestinal symptoms and the inconvenience of regular self-injections may deter adherence for certain patients.[169] Recognizing the challenges associated with long-term adherence, pharmaceutical companies are innovating through the development of more-convenient delivery methods
Bellwether Trials: These initial test cases, critical for gauging broader settlement values and liability theories, are expected to begin mid-2026
Six passed BPC-157, KPV, and TB-500 each by an 8-6 margin, MOTS-C by 7-5, Semax by 8-5, and Epitalon by 7-5
New England Journal of Medicine , 373(1), 48-59